NCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
Clinical Trials
16 trialsNCT03863860 2025-07-03
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04517357 2025-02-24
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT06541314 2024-11-27
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06552858 2024-08-14
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06188455 2024-01-03
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
The First Affiliated Hospital of Xiamen University
Phase 3 Not yet recruiting
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT06081595 2023-10-13
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fudan University
Phase 2 Not yet recruiting
NCT06063070 2023-10-02
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05585281 2023-07-28
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03075462 2022-07-01
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03509636 2022-07-01
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown
NCT02575651 2019-06-17
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed